Substituted pyrrolopyridine-derivatives

US11427578B1 · kind B1 · utility

Assignees

• Bayer Pharma Aktiengesellschaft · DE
• BAYER HEALTHCARE LLC · DE
• Deutsches Krebsforschungszentrum · DE

Inventors

• Jeffrey Stuart MOWAT · Berlin, DE
• Bernd Buchmann · Hohen Neuendorf, DE
• Nuria Aiguabella Font · Berlin, DE
• Gabriele LEDER · Berlin, DE
• Rafael CARRETERO · Heidelberg, DE
• Olaf Panknin · Berlin, DE
• Roland Neuhaus · Berlin, DE
• Robin Michael MEIER · Wain, DE
• Sandra BERNDT · Hohen Neuendorf, DE
• Kirstin Petersen · Berlin, DE
• Rienk Offringa · Leiden, NL

Key dates

• Filing date: Jul 12, 2018
• Grant date: Aug 30, 2022
• Expiry date: Jul 15, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K45/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to protein-inhibitory substituted pyrrolopyridine derivatives of formula (I), in which A, X, R1, R2a, R2b, R3a, R3b, R4a and R4b are as defined herein, to pharmaceutical compositions and combinations comprising the compounds according to the invention, and to the prophylactic and therapeutic use of the inventive compounds, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for neoplastic disorders, respectively cancer or conditions with dysregulated immune responses or other disorders associated with aberrant MAP4K1 signaling, as a sole agent or in combination with other active ingredients. The present invention further relates to the use, respectively to the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of protein inhibitors in benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, in neurodegenerative disorders, in inflammatory disorders, in atherosclerotic disorders and in male fertility control.